We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Instrumentation Laboratory, Inova Diagnostics and Biokit Organizationally Transform and Now Share Werfen Name

By LabMedica International staff writers
Posted on 13 Jul 2021
Werfen (Barcelona, Spain) companies, including Instrumentation Laboratory (IL), Inova Diagnostics (Inova), and Biokit, are uniting under one name and one brand - Werfen. More...
As part of this effort, the company has completed organizational transitions and adopted a new global brand identity, including a new corporate logo.

While IL, Inova and Biokit have been part of Werfen since 1992, 2009, and 1973, respectively, they will now be known simply as Werfen. The company has been known as Werfen outside of North America since 2014. The strategic hubs for the Company's key business lines will now be led by Chief Operating Officers, and operate as Werfen Headquarters and Technology Centers. Management and organization of Werfen's Commercial Operations in North America will now be consolidated. Field Service and Customer Service functions will be unified across business lines, while Sales, Applications, Marketing and Technical Support will remain specialized.

With a new logo and brand colors, Werfen adopts a new brand identity - evoking innovation and humanity. The new Werfen logo is modern, strong and singular, signifying unity in the company's quest to deliver innovation after innovation, for every patient whose life could depend upon the quality of a test result. The new logo will be incorporated into the company's products and communication vehicles gradually, over time. The legal names for IL, Inova and Biokit, and any contracts or purchasing agreements, are unaffected by this change.

"This transformation represents a natural evolution for Werfen, strengthening our global leadership position in specialized diagnostics, and positively impacting our ability to drive innovation and support our customers," said Carlos Pascual, CEO at Werfen. "By sharing one global identity, with the same vision and strategic objectives, our teams around the world will maximize collaboration to set new standards for products and services in Hemostasis, Acute Care, Autoimmunity and OEM diagnostics."

Related Links:
Werfen


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic CLIA Analyzer
Shine i9000
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.